GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that adult non-flu vaccination rates in the US have rebounded from the impact of the COVID-19 pandemic. According to data from GSK’s Vaccine Track platform, immunization rates between the first and third quarters of 2023 were 1% higher than those recorded in the same period in 2019. This increase was partly attributed to healthcare programs that were bolstered by the government’s 2022 Inflation Reduction Act (IRA).
In conjunction with this positive trend, GSK announced its commitment to grant up to USD 2 million to non-profit organizations and community groups that are dedicated to promoting adult immunization and health equity. This financial support aims to further enhance vaccination rates and address health disparities among adult populations.- Flcube.com
